Beyond Air

XAIR

시가총액 US$213만

Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 GARDEN CITY, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026.

GARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, which is being held at the Waldorf Astoria New York, New York on September 9-11, 2026.

GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD).

Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments GARDEN CITY, N.Y., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) today announced that they have entered into a definitive agreement under which UNIVO Pharmaceutical Industries Ltd (“UNIVO”) Univo Pharmaceutical Industries Ltd.

Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript

Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027

GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its quarter ended June 30, 2026 on Thursday, August 13, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 a.m. Eastern Time (ET) the same day.

GARDEN CITY, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it has entered into a securities purchase agreement for the purchase and sale of (i) an aggregate of 167,011 shares of the Company's common stock and accompanying warrants at a combined purchase price of $5.66 per share to certain institutional investors (“Purchase Price”) and a combined purchase price of $5.76 per share to certain of the Company's directors and officers, and (ii) in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 1,638,835 shares of the Company's common stock and accompanying warrants at a combined purchase price of $5.6599, representing the Purchase Price less the $0.0001 exercise price of each pre-funded warrant.

Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript

Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026